NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis Group issued an update on its business during the third quarter of fiscal year 2016, and announced €32.7 million ($34.7 million) in private financing and a US distribution deal with Thermo Fisher Scientific for its Idylla diagnostics platform and assays.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.